Breaking News Instant updates and real-time market news.

VRTX

Vertex

$153.20

-0.41 (-0.27%)

10:52
09/19/17
09/19
10:52
09/19/17
10:52

Vertex to present 11 abstracts from CF R&D program at NACFC

Vertex Pharmaceuticals announced that 11 abstracts from its cystic fibrosis research and development program will be presented at the annual North American Cystic Fibrosis Conference in Indianapolis, November 2 to 4, 2017. Previously announced data from the Phase 3 EVOLVE and EXPAND studies of the investigational tezacaftor/ivacaftor combination in people with CF ages 12 and older who have certain mutations in the cystic fibrosis transmembrane conductance regulator gene will be presented for the first time. Additionally, data from the Phase 3 extension study of ORKAMBI in children with CF ages 6 to 11 who have two copies of the F508del mutation and real-world KALYDECO data will be presented. The company also submitted an abstract for the late-breaking poster session with previously announced Phase 1 and Phase 2 data for three different next-generation correctors -- VX-440, VX-152 and VX-659 -- in triple combination regimens with tezacaftor and ivacaftor in people with CF who have one F508del mutation and one minimal function mutation and in people with two copies of the F508del mutation. Collectively, the data at the Conference demonstrate continued progress across the company's CF program goals of providing enhanced treatment options for more people, demonstrating the disease-modifying effects of CFTR modulators, and expanding CFTR treatment options to all people with CF through the development of new medicines.

VRTX Vertex
$153.20

-0.41 (-0.27%)

07/19/17
07/19/17
DOWNGRADE
Target $174

Neutral
Vertex downgraded to Neutral on valuation after CF data jump at UBS
As previously reported, UBS analyst Carter Gould downgraded Vertex to Neutral from Buy, arguing that the valuation of its cystic fibrosis franchise appears "full" following the run-up in the stock on the heels of the company's data from Phase 1 and Phase 2 studies of three different triple combination regimen. Gould raised his price target on Vertex shares to $174 from $135, as he sees visibility for the CF franchise to approach $8B in revenue by the end of the 2020s.
07/27/17
OPCO
07/27/17
NO CHANGE
Target $175
OPCO
Outperform
Vertex price target raised to $175 from $150 at Oppenheimer
Oppenheimer analyst Hartaj Singh raised his price target for Vertex to $175 from $150 following Q2 results and business update to investors. The analyst continues to be bullish on Vertex and would urge investors that any potential sustained weakness should be a buying opportunity. Singh reiterates an Outperform rating on the shares.
09/07/17
LEER
09/07/17
NO CHANGE
LEER
Alexion, Celgene top picks at Leerink
Leerink analyst Geoffrey Porges notes large cap biotech stocks have performed strongly this year and have reversed some of the wide discount they were carrying compared to their history and to other medical products sectors. Further, he points out consensus revenue and earnings estimates for biotech companies have started to trend positively, after negative revisions earlier in the year. Porges still sees significant upside for many of the names in his coverage, and he anticipates that further appreciation can occur on the basis of recovering sentiment and multiples, further estimate revisions toward his current models, and confirmation of option value for unpriced pipeline opportunities. The analyst top picks are now Alexion (ALXN), Celgene (CELG), Regeneron (REGN), and Vertex (VRTX). Among his Market Perform rated stocks, his preference would be for AbbVie (ABBV).
09/14/17
RBCM
09/14/17
INITIATION
Target $175
RBCM
Outperform
Vertex initiated with an Outperform at RBC Capital
RBC Capital analyst Brian Abrahams started Vertex Pharmaceuticals with an Outperform rating and $175 price target. The analyst is bullish on the company's cystic fibrosis triple combo and its long-term competitive positioning.

TODAY'S FREE FLY STORIES

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$54.63

4.63 (9.26%)

06:52
02/20/18
02/20
06:52
02/20/18
06:52
Technical Analysis
Direxion Daily Junior Gold Miners Index Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLH

William Lyon Homes

$25.73

0.31 (1.22%)

06:51
02/20/18
02/20
06:51
02/20/18
06:51
Hot Stocks
William Lyon Homes to acquire RSI Communities for about $460M »

William Lyon Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

VXX

iPath S&P 500 VIX Short-Term Futures

$42.15

0.61 (1.47%)

06:51
02/20/18
02/20
06:51
02/20/18
06:51
Technical Analysis
iPath S&P 500 VIX Short-Term Futures: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMAX

Imax

$22.60

-0.3 (-1.31%)

06:51
02/20/18
02/20
06:51
02/20/18
06:51
Initiation
Imax initiated  »

Imax assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 05

    Mar

TVIX

VelocityShares Daily 2x VIX Short-Term ETN

$7.95

0.17 (2.19%)

06:50
02/20/18
02/20
06:50
02/20/18
06:50
Technical Analysis
VelocityShares Daily 2x VIX Short-Term ETN: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TORC

ResTORbio

$18.76

0.54 (2.96%)

06:50
02/20/18
02/20
06:50
02/20/18
06:50
Initiation
ResTORbio initiated  »

ResTORbio initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TVPT

Travelport

$13.22

0.14 (1.07%)

06:50
02/20/18
02/20
06:50
02/20/18
06:50
Earnings
Travelport sees FY18 adj. EPS $1.34-$1.46, consensus $1.44 »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 26

    Feb

  • 30

    May

CVRS

Corindus

$0.95

-0.0071 (-0.74%)

06:49
02/20/18
02/20
06:49
02/20/18
06:49
Hot Stocks
Corindus receives FDA 510(k) clearance for CorPath GRX System »

Corindus Vascular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

SVXY

ProShares Short VIX Short-Term Futures

$12.69

-0.22 (-1.70%)

06:49
02/20/18
02/20
06:49
02/20/18
06:49
Technical Analysis
ProShares Short VIX Short-Term Futures: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BWXT

BWX Technologies

$64.12

-0.19 (-0.30%)

06:49
02/20/18
02/20
06:49
02/20/18
06:49
Hot Stocks
BWX Technologies subsidary awarded contracts for C$30M »

BWX Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

WMT

Walmart

$104.78

1.55 (1.50%)

06:48
02/20/18
02/20
06:48
02/20/18
06:48
Hot Stocks
Breaking Hot Stocks news story on Walmart »

Walmart sees FY19 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 28

    Feb

  • 07

    Mar

WMT

Walmart

$104.78

1.55 (1.50%)

06:48
02/20/18
02/20
06:48
02/20/18
06:48
Hot Stocks
Walmart says moving to annual guidance framework with quarterly updates »

Walmart also commented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 28

    Feb

  • 07

    Mar

SLDB

Solid Biosciences

$24.93

-1.34 (-5.10%)

, SRPT

Sarepta

$64.00

0.86 (1.36%)

06:48
02/20/18
02/20
06:48
02/20/18
06:48
Initiation
Solid Biosciences, Sarepta initiated  »

Solid Biosciences…

SLDB

Solid Biosciences

$24.93

-1.34 (-5.10%)

SRPT

Sarepta

$64.00

0.86 (1.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

USO

United States Oil Fund

$12.38

0.05 (0.41%)

06:47
02/20/18
02/20
06:47
02/20/18
06:47
Technical Analysis
United States Oil Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TVPT

Travelport

$13.22

0.14 (1.07%)

06:47
02/20/18
02/20
06:47
02/20/18
06:47
Earnings
Travelport reports Q4 adj. EPS 35c, consensus 23c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 26

    Feb

  • 30

    May

WMT

Walmart

$104.78

1.55 (1.50%)

06:47
02/20/18
02/20
06:47
02/20/18
06:47
Earnings
Walmart sees FY19 net sales growth 1.5%-2%, consensus $511.94B »

Sees FY19 effective tax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 28

    Feb

  • 07

    Mar

CDXC

ChromaDex

$5.39

0.01 (0.19%)

06:47
02/20/18
02/20
06:47
02/20/18
06:47
Hot Stocks
ChromaDex announces two new collaborative human clinical studies on NIAGEN »

ChromaDex announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

XOP

SPDR Oil Exploration and Production Fund

$33.92

-0.17 (-0.50%)

06:47
02/20/18
02/20
06:47
02/20/18
06:47
Technical Analysis
SPDR Oil Exploration and Production Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$83.31

0.37 (0.45%)

06:47
02/20/18
02/20
06:47
02/20/18
06:47
Earnings
Medtronic backs FY18 adjusted EPS growth view of 9%-10%, consensus $4.77 »

In fiscal year 2018, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 14

    Mar

  • 23

    Mar

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$31.88

0.71 (2.28%)

06:46
02/20/18
02/20
06:46
02/20/18
06:46
Technical Analysis
VelocityShares 3x Inv Natural Gas ETN: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGS

PlayAGS

$19.95

0.11 (0.55%)

06:46
02/20/18
02/20
06:46
02/20/18
06:46
Initiation
PlayAGS initiated  »

PlayAGS initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRD

Tailored Brands

$23.31

-0.01 (-0.04%)

06:45
02/20/18
02/20
06:45
02/20/18
06:45
Hot Stocks
Tailored Brands launches three week custom delivery »

Men's Wearhouse and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

TFX

Teleflex

$267.89

2.28 (0.86%)

06:45
02/20/18
02/20
06:45
02/20/18
06:45
Hot Stocks
Teleflex subsidiary announces FDA cleared new indication for UroLift »

NeoTract, a wholly owned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

  • 01

    Mar

  • 14

    Mar

ADM

Archer Daniels

$43.13

0.265 (0.62%)

, SYT

Syngenta

06:45
02/20/18
02/20
06:45
02/20/18
06:45
Periodicals
ADM, Syngenta settle lawsuit over biotech corn exports to China, Reuters reports »

Archer Daniels Midland…

ADM

Archer Daniels

$43.13

0.265 (0.62%)

SYT

Syngenta

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$83.31

0.37 (0.45%)

06:45
02/20/18
02/20
06:45
02/20/18
06:45
Earnings
Medtronic reports Q3 adjusted EPS $1.17, consensus $1.17 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 14

    Mar

  • 23

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.